Lantern Pharma Inc. (Nasdaq: LTRN)

💡In case you missed it - the last Lantern Pharma Inc. (Nasdaq: LTRN) Pharma Webinar Wednesday of the year - Power of AI in Drug Development – Predicting Blood Brain Barrier Permeability with RADR featuring our #datascientist Rick Fontenot, M.S., is now available on our #youtube channel! https://lnkd.in/gqYi2xKa Thank you everyone for joining the Lantern Pharma Webinar Wednesdays! We look forward to your continued excitement and engagement in upcoming webinars and events, so stay tuned for what’s coming in 2025! Here are some highlights of the webinar:  📍Rick discussed what is Blood Brain Barrier and the reasons why it is so important in developing new therapies for CNS cancers.  📍Rick shared RADR AI insights on BBB - How Lantern build BBB models that has over 90% accuracy 📍Rick talked about the true power of predicting BBB permeability with RADR, in both small and large scale of drug development. Make sure you check out the full webinar here: https://lnkd.in/gqYi2xKa

Happening TOMORROW, December 11th, 1PM Eastern time - Register NOW for the last Lantern Pharma Webinar Wednesday of the year - Power of AI in Drug Development – Predicting Blood Brain Barrier Permeability with RADR https://bit.ly/4gy7jtF https://bit.ly/4gy7jtF Featuring Rick Fontenot, data scientist of Lantern Pharma Inc. (Nasdaq: LTRN), we will be discussing 📍 What is Blood Brain Barrier and why is it so important? 📍 RADR AI insights on BBB -using machine learning : How did we build BBB models and how accurate is it? 📍 Power of predicting BBB permeability with RADR …and so much more! Register now: https://bit.ly/4gy7jtF to join the free webinar!

First Patient Enrolled in #Taiwan for Phase 2 HARMONIC™ Trial! 🚀 We’re thrilled to announce the first patient enrollment in Taiwan for our Phase 2 HARMONIC™ clinical trial evaluating LP-300 in never-smoker NSCLC patients. This milestone highlights our commitment to delivering targeted therapies to underserved populations. Key Highlights: 🔬 Over 50% of lung cancer cases in Taiwan occur in never-smokers.   🔬 LP-300 focuses on never-smoker #NSCLC, a unique disease entity requiring precision therapy.   🔬 This follows the encouraging preliminary results of 86% clinical benefit rate and 43% objective response rate among the first seven patients. 🔬 The trial is actively enrolling in multiple sites in the U.S., Japan, and Taiwan. We’re advancing progress with the goal of improving outcomes for never-smoker NSCLC patients worldwide. Stay tuned for updates! Read the full release: https://bit.ly/4g3Nme1 Learn more about the trial: www.harmonictrial.com

Register NOW for the last Lantern Pharma Webinar Wednesday of the year - Power of AI in Drug Development – Predicting Blood Brain Barrier Permeability with RADR - Happening on December 11th, 1PM Eastern time. https://bit.ly/4gy7jtF https://bit.ly/4gy7jtF Featuring Rick Fontenot, data scientist of Lantern Pharma Inc. (Nasdaq: LTRN), we will be discussing 📍 What is Blood Brain Barrier and why is it so important? 📍 RADR AI insights on BBB -using machine learning : How did we build BBB models and how accurate is it? 📍 Power of predicting BBB permeability with RADR …and so much more! Register now: https://bit.ly/4gy7jtF to join the free webinar!

Earlier this week, we announced that Lantern Pharma Inc. (Nasdaq: LTRN) ’s Investigational Drug-Candidate, LP-184, Received Fast-Track Designation in #TripleNegativeBreastCancer(TNBC) from #FDA Learn more about our drug candidate LP-184 and the importance of its Fast-Track designation in driving the development of innovative and effective therapies for TNBC patients. Read the full release: https://bit.ly/3CX5Bn0 Visit our website: www.lanternpharma.com Learn more about the ongoing trial: ltrntrials.link/lp184

🚀Exciting News!!! Today, we announced that Lantern Pharma Inc. (Nasdaq: LTRN) ’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in #TripleNegativeBreastCancer(TNBC) from #FDA   Why is it exciting... 📍This is the second Fast Track Designation granted to LP-184 in 2024, following the designation for Glioblastoma (GBM) announced in October 2024. 📍Fast Track Designation is designed to expedite FDA review of important new drugs to treat serious conditions and fill an unmet medical need. 📍Fast Track Designation for LP-184 recognizes #TNBC as a serious condition impacting approximately 29,000 patients annually in the US, with over 50% of patients relapsing within 3-5 years. 📍LP-184 is currently being evaluated in a Phase 1A clinical trial (NCT05933265) across multiple solid tumor indications, including TNBC. Read the full release: https://bit.ly/3CX5Bn0 Visit our website: www.lanternpharma.com Learn more about the ongoing trial: ltrntrials.link/lp184

🗓️ Save the date - December 11th, 1PM Eastern time - for the last Lantern Pharma Webinar Wednesday of the year - Power of AI in Drug Development – Predicting Blood Brain Barrier Permeability with RADR.   https://bit.ly/4gy7jtF https://bit.ly/4gy7jtF Featuring Rick Fontenot, data scientist of Lantern Pharma Inc. (Nasdaq: LTRN), we will be discussing 📍 What is Blood Brain Barrier and why is it so important? 📍 RADR AI insights on BBB -using machine learning : How did we build BBB models and how accurate is it? 📍 Power of predicting BBB permeability with RADR …and so much more! Register now: https://bit.ly/4gy7jtF to join the free webinar!

#SNO2024 poster -A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of LP-184 alone and in combination with Spironolactone in IDH wild type Glioblastoma at First Progression (Abstract Code:CTNI-29)- is now available on our website! Last week, we were excited to attend and present at the #SNO2024 Annual Meeting. Our senior research scientist Aditya Kulkarni, PhD., shared some of the innovative work in collaboration with Johns Hopkins Medicine and were able to connect with the #CancerResearch community. Check out the full poster at our website to learn more: https://bit.ly/3Him1Wm

Today, November 22nd, at 7:30PM Central time, Lantern Pharma Inc. (Nasdaq: LTRN) is presenting at the 2024 Society for Neuro-Oncology (SNO) annual meeting. Our senior research scientist Aditya Kulkarni, PhD will be presenting with Karisa Schreck, MD, PhD of Johns Hopkins Medicine. Stay tuned for the poster presentation- "A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of LP-184 alone and in combination with Spironolactone in IDH wild type #Glioblastoma at First Progression (Abstract Code:CTNI-29)" Learn more about the #SNO2024 meeting :https://lnkd.in/ejbVQkgu Visit our website: www.lanternpharma.com

Lantern Pharma Inc. (Nasdaq: LTRN) announced that the first patient has been dosed in Japan for the Phase 2 HARMONIC™ clinical trial for LP-300 in never-smoker patients with non-small cell lung cancer #NSCLC. This marks a significant expansion of the Harmonic™ trial into Asia. But why Asia? 📍Non-small cell lung cancer (NSCLC) in never smokers occurs at rates 2 to 3 times higher in East Asian countries versus the US and Europe. 📍2 in 5 of all lung cancer patients in East Asia are never smokers 📍More than 50% of lung cancer patients in Taiwan and more than 32% in Japan are never smokers. Check out the full press release to learn more about our significant milestone with the expansion of the HARMONIC™ trial into Asia! Read the full release: https://bit.ly/3UVasv5 Learn more about the trial: harmonictrial.com Clinicaltrial.gov (NCT05456256): https://lnkd.in/eKHWFphD